. Author manuscript; available in PMC: 2015 Nov 1.

Published in final edited form as: Clin Exp Ophthalmol. 2014 May 5;42(8):713–721. doi: 10.1111/ceo.12325

Table 5. Results of regression analyses: outcome: baseline to best logmar at any follow-up visit.

Model/Predictors		Coefficient	Std Error	p-value
Model 1:	R² = 0.0076
	High-dose Levodopa	-0.0132	0.0233	0.5750
	Low-dose Levodopa	-0.0055	0.0233	0.8128
	(Default: Placebo)
Model 2:	R² = 0.0233
	High-dose Levodopa	-0.0052	0.0261	0.8443
	Low-dose Levodopa	-0.0017	0.0250	0.9446
	(Default: Placebo)
	OCA1A	0.0143	0.0265	0.5937
	OCA1B	-0.0072	0.0246	0.7713
	(Default: OCA2; HPS-1 omitted)
Model 3:	R² = 0.0707
	High-dose Levodopa	0.0000	0.0241	0.9992
	Low-dose Levodopa	.0010	0.0231	0.9643
	(Default: Placebo)
	Female Gender	-0.0033	0.0197	0.1028
Model 4:	R² = 0.0469
	High-dose Levodopa	0.0151	0.0231	0.5188
	Low-dose Levodopa	-0.0148	0.0241	0.5443
	(Default: Placebo)
	Age, years	0.0010	0.0008	0.2007
Model 5:	R² = 0.0426
	High-dose Levodopa	0.0115	0.0232	0.6219
	Low-dose Levodopa	0.0146	0.0235	0.6585
	(Default: Placebo)
	Age <14	-0.0255	0.0200	0.2277